Hikma Pharmaceuticals (OTCMKTS:HKMPF) Stock Rating Upgraded by Royal Bank of Canada

Royal Bank of Canada upgraded shares of Hikma Pharmaceuticals (OTCMKTS:HKMPF) from a hold rating to a moderate buy rating in a report issued on Tuesday morning,Zacks.com reports.

Hikma Pharmaceuticals Price Performance

Shares of HKMPF opened at $24.87 on Tuesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.66 and a quick ratio of 0.98. Hikma Pharmaceuticals has a 1-year low of $21.90 and a 1-year high of $26.50. The firm has a 50 day simple moving average of $24.48 and a 200-day simple moving average of $24.92.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.